Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

McMaster University

$124,000.00

Toward a rational and novel therapy for clostridium difficile infection

FY 2013-14

Summary
Clostridium difficile (C. difficile) infection (CDI) is one of the most frequent causes of health care-associatedinfectious diseases in Canada and other industrialized countries, with a mortality rate of approximately 6%. ACanadian study has reported that CDI for in-hospital adult patients is 65 per 100,000 patient-days in Canada. Inaddition, recurrence rates following standard antibiotics therapy are high, particularly for the elderly (greaterthan 40% for those over the age 65). Healthy bacteria in the colon are the key defense against CDI; the primaryrisk factor for developing CDI is the use of antibiotics because they kill these healthy bacteria allowing C.difficile to proliferate. Current treatment for CDI relies on other antibiotics (metronidazole or vancomycin),which lends itself to treatment failure as CDI is caused by exposure to antibiotic(s) to begin with. Fecaltransplantation, where a bacteria mixture extracted from a stool sample from a healthy, screened individual isrectally administered to an affected patient, is developing into a highly effective therapy as it leads torestoration of healthy bacterial population in the infected patient and eradicating C. difficile. However, thistherapy also comes with challenges: the need to identify a suitable donor for each patient; the lengthy time andcost required to screen for transmissible pathogens in the donors; as well as negative psychological factors.Given the unacceptable failure and recurrence rates using standard therapy, an alternative treatment is ofparamount importance. Our team sets out to better understand CDI and to develop a rational and novel,microbiota based therapy to combat CDI. We expect to generate valuable information about innate bacterialcommunity assembly patterns in both CDI patients and healthy individuals, establish effective microbiota tocombat proliferation of C. difficile, develop novel probes for C. difficile surveillance, and most importantly setup the stage to pursue microbiota transplantation therapy as a new approach to combating CDI.
Program
Collaborative Health Research Projects
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
413548-2012
Name nom
Li, Yingfu
Department département
Biochemistry and Biomedical Sciences
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2012
Award amount
124000
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
2 & 3
Nb partie
3
Application title
Toward a rational and novel therapy for clostridium difficile infection
Keyword
NSERC
Application summary
Clostridium difficile (C. difficile) infection (CDI) is one of the most frequent causes of health care-associatedinfectious diseases in Canada and other industrialized countries, with a mortality rate of approximately 6%. ACanadian study has reported that CDI for in-hospital adult patients is 65 per 100,000 patient-days in Canada. Inaddition, recurrence rates following standard antibiotics therapy are high, particularly for the elderly (greaterthan 40% for those over the age 65). Healthy bacteria in the colon are the key defense against CDI; the primaryrisk factor for developing CDI is the use of antibiotics because they kill these healthy bacteria allowing C.difficile to proliferate. Current treatment for CDI relies on other antibiotics (metronidazole or vancomycin),which lends itself to treatment failure as CDI is caused by exposure to antibiotic(s) to begin with. Fecaltransplantation, where a bacteria mixture extracted from a stool sample from a healthy, screened individual isrectally administered to an affected patient, is developing into a highly effective therapy as it leads torestoration of healthy bacterial population in the infected patient and eradicating C. difficile. However, thistherapy also comes with challenges: the need to identify a suitable donor for each patient; the lengthy time andcost required to screen for transmissible pathogens in the donors; as well as negative psychological factors.Given the unacceptable failure and recurrence rates using standard therapy, an alternative treatment is ofparamount importance. Our team sets out to better understand CDI and to develop a rational and novel,microbiota based therapy to combat CDI. We expect to generate valuable information about innate bacterialcommunity assembly patterns in both CDI patients and healthy individuals, establish effective microbiota tocombat proliferation of C. difficile, develop novel probes for C. difficile surveillance, and most importantly setup the stage to pursue microbiota transplantation therapy as a new approach to combating CDI.
McMaster University - $124,000 Grant (2013-14) | Canada Spends